Aptevo Therapeutics Stock Beta
| APVO Stock | USD 0.35 0.01 2.94% |
Aptevo Therapeutics fundamentals help investors to digest information that contributes to Aptevo Therapeutics' financial success or failures. It also enables traders to predict the movement of Aptevo Stock. The fundamental analysis module provides a way to measure Aptevo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aptevo Therapeutics stock.
Aptevo | Beta |
Aptevo Therapeutics Company Beta Analysis
Aptevo Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Aptevo Therapeutics Beta | 5.07 |
Most of Aptevo Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aptevo Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Aptevo Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Aptevo Therapeutics is extremely important. It helps to project a fair market value of Aptevo Stock properly, considering its historical fundamentals such as Beta. Since Aptevo Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aptevo Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aptevo Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Aptevo Therapeutics has a Beta of 5.066. This is much higher than that of the Biotechnology sector and 264.46% higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Aptevo Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aptevo Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aptevo Therapeutics could also be used in its relative valuation, which is a method of valuing Aptevo Therapeutics by comparing valuation metrics of similar companies.Aptevo Therapeutics is currently under evaluation in beta category among its peers.
Aptevo Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Aptevo Therapeutics from analyzing Aptevo Therapeutics' financial statements. These drivers represent accounts that assess Aptevo Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Aptevo Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 26.7M | 124.3M | 36.9M | 11.9M | 2.2M | 2.1M | |
| Enterprise Value | 37.5M | 111.7M | 8.6M | (1.2M) | (9.3M) | (8.8M) |
Aptevo Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Aptevo Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Aptevo Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aptevo Therapeutics' value.| Shares | Qube Research & Technologies | 2024-06-30 | 500 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 388 | Bank Of America Corp | 2024-06-30 | 160 | Advisor Group Holdings, Inc. | 2024-06-30 | 45.0 | Jpmorgan Chase & Co | 2024-06-30 | 43.0 | Wells Fargo & Co | 2024-06-30 | 33.0 | Pnc Financial Services Group Inc | 2024-09-30 | 3.0 | Baader Bank Inc | 2024-09-30 | 0.0 | Truvestments Capital Llc | 2024-06-30 | 0.0 | Hudson Bay Capital Management Lp | 2024-09-30 | 935.6 K | Sabby Management Llc | 2024-06-30 | 501.5 K |
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Aptevo Therapeutics will likely underperform.
Aptevo Fundamentals
| Return On Equity | -2.51 | ||||
| Return On Asset | -0.73 | ||||
| Current Valuation | 3.3 M | ||||
| Shares Outstanding | 18.51 M | ||||
| Shares Owned By Insiders | 0.03 % | ||||
| Shares Owned By Institutions | 6.93 % | ||||
| Number Of Shares Shorted | 1.2 M | ||||
| Price To Earning | 2.48 X | ||||
| Price To Book | 1.41 X | ||||
| Price To Sales | 1.61 X | ||||
| Gross Profit | 3.11 M | ||||
| EBITDA | (28.31 M) | ||||
| Net Income | (17.41 M) | ||||
| Cash And Equivalents | 29.43 M | ||||
| Cash Per Share | 5.78 X | ||||
| Total Debt | 5.4 M | ||||
| Debt To Equity | 0.47 % | ||||
| Current Ratio | 4.48 X | ||||
| Book Value Per Share | 0.26 X | ||||
| Cash Flow From Operations | (11.73 M) | ||||
| Short Ratio | 0.05 X | ||||
| Earnings Per Share | (11.24) X | ||||
| Target Price | 8.0 | ||||
| Number Of Employees | 40 | ||||
| Beta | 5.07 | ||||
| Market Capitalization | 6.22 M | ||||
| Total Asset | 24.84 M | ||||
| Retained Earnings | (223.45 M) | ||||
| Working Capital | 11.84 M | ||||
| Current Asset | 71.41 M | ||||
| Current Liabilities | 19.54 M | ||||
| Net Asset | 24.84 M |
About Aptevo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aptevo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aptevo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aptevo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Aptevo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptevo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptevo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Aptevo Stock
The ability to find closely correlated positions to Aptevo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptevo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptevo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptevo Therapeutics to buy it.
The correlation of Aptevo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptevo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptevo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptevo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Aptevo Therapeutics Piotroski F Score and Aptevo Therapeutics Altman Z Score analysis. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.24) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (2.51) |
The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptevo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.